| Market Cap | 883.22M | P/E | - | EPS this Y | 2,093.00% | Ern Qtrly Grth | - |
| Income | 1.72B | Forward P/E | -4.78 | EPS next Y | -110.80% | 50D Avg Chg | -18.00% |
| Sales | 1.69M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -19.00% |
| Dividend | N/A | Price/Book | 58.36 | EPS next 5Y | - | 52W High Chg | -42.00% |
| Recommedations | 3.00 | Quick Ratio | 5.85 | Shares Outstanding | 14.48M | 52W Low Chg | 61.00% |
| Insider Own | 23.55% | ROA | - | Shares Float | 7.68M | Beta | - |
| Inst Own | 67.42% | ROE | - | Shares Shorted/Prior | 677.72K/752.85K | Price | 20.25 |
| Gross Margin | - | Profit Margin | 101,974.22% | Avg. Volume | 355,133 | Target Price | 11.00 |
| Oper. Margin | -160,898.00% | Earnings Date | Aug 13 | Volume | 482,838 | Change | -1.32% |
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
| JMP Securities | Market Perform | Jul 23, 24 |
| JMP Securities | Market Perform | Jan 23, 24 |
| JMP Securities | Market Outperform | Nov 20, 23 |
| JMP Securities | Outperform | Aug 23, 23 |
| JMP Securities | Market Outperform | May 10, 23 |
| JMP Securities | Market Outperform | Mar 8, 23 |
| Credit Suisse | Outperform | Mar 7, 23 |
| Credit Suisse | Outperform | Nov 8, 22 |
| Evercore ISI Group | Outperform | Oct 5, 22 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP | 10% Owner 10% Owner | Aug 28 | Buy | 19.35 | 511,627 | 9,899,982 | 511,627 | 08/30/23 |
| Eckelman Brendan P. | Chief Scientific Off.. Chief Scientific Officer | Feb 01 | Sell | 25.27 | 40,000 | 1,010,800 | 2,075,553 | 02/02/23 |
| Lappe Mark | Chief Executive Offi.. Chief Executive Officer | Jan 23 | Sell | 25.73 | 26,000 | 668,980 | 2,486,252 | 01/24/23 |
| Kayyem Jon Faiz | Director Director | Jan 23 | Sell | 25.2631 | 9,500 | 239,999 | 3,224,301 | 01/23/23 |
| Eckelman Brendan P. | Chief Scientific Off.. Chief Scientific Officer | Jan 03 | Sell | 23.99 | 40,000 | 959,600 | 2,115,553 | 01/04/23 |
| Eckelman Brendan P. | Chief Scientific Off.. Chief Scientific Officer | Nov 01 | Sell | 33.62 | 40,000 | 1,344,800 | 2,195,553 | 11/02/22 |
| Lappe Mark | Chief Executive Offi.. Chief Executive Officer | Oct 17 | Sell | 30.22 | 26,000 | 785,720 | 2,564,252 | 10/18/22 |
| Eckelman Brendan P. | Chief Scientific Off.. Chief Scientific Officer | Sep 06 | Sell | 15.26 | 40,000 | 610,400 | 2,435,553 | 09/07/22 |
| Eckelman Brendan P. | Chief Scientific Off.. Chief Scientific Officer | Jul 07 | Sell | 17.17 | 40,000 | 686,800 | 2,515,553 | 07/08/22 |